Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

Results Reported From Three NCI-Sponsored Clinical Trials

SOUTH SAN FRANCISCO, CA June 28, 2007 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced results from the analyses of three Phase II clinical trials of ispinesib administered as monotherapy, one in patients with hepatocellular cancer, one in patients with melanoma, and one in patients with hormone-refractory prostate cancer. Ispinesib is a novel small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division. Ispinesib has arisen from a broad strategic collaboration between Cytokinetics and GlaxoSmithKline (GSK) to discover, develop and commercialize novel small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases. All three clinical trials were sponsored by the National Cancer Institute (NCI).

A Phase II clinical trial designed to evaluate the safety and efficacy of ispinesib in the treatment of patients with locally advanced, recurrent or metastatic hepatocellular cancer was recently completed. In Stage 1 of this two-stage clinical trial, 15 patients received ispinesib as monotherapy at 18 mg/m2 as a 1-hour intravenous infusion every 21 days. The trial s primary endpoint was objective response as determined using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. This trial was designed to require at least 1 confirmed partial or complete response out of 15 evaluable patients in Stage 1 in order to proceed to Stage 2. The best overall response was stable disease seen in 7 of the 15 patients treated. In this clinical trial, ispinesib did not satisfy the criteria for advancement to the second stage and therefore recruitment to Stage 2 was not opened. The toxicity profile was consistent with other previously reported Phase II clinical trials of ispinesib. A manuscript is being prepared.

A Phase
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 Swedish ... Inc. today announced that the Committee for Medicinal Products ... (EMA) has adopted a positive opinion for the use ... adult men with Peyronie,s disease with a palpable plaque ... the start of therapy. The use of ...
(Date:12/22/2014)... , Dec, 22, 2014  Eiger BioPharmaceuticals ... 2a study of lonafarnib in patients with chronic ... conducted at the National Institutes of Health (NIH) ... .  The double-blinded, randomized, placebo-controlled, dose ascending study ... daily and 200 mg twice daily for 28 ...
(Date:12/22/2014)... TWi Biotechnology, Inc., today announced that ... TWi Biotechnology,s lead drug candidate, from The State ... for patent application numbered 201180018154.8.  This patent ... metabolite for treatment of type II diabetes.  The ... AC-201 for type II diabetes, and provides a ...
Breaking Medicine Technology:Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3
... WIRE)--Jun 27, 2007 - Opexa,Therapeutics, Inc. (NASDAQ:OPXA), ... of cell therapies, presented,poster presentations at the ... Meeting (ISSCR) in Cairns, Queensland, Australia,from June ... of the International,Society for Cellular Therapy (ISCT) ...
... IIa Clinical Trial in Type 2,Diabetes Patients ... Transition,Therapeutics Inc. ("Transition") , today announces the ... indicating that 4-weeks of,daily treatments with gastrin-based ... control parameters, including,haemoglobinA1C (HbA1c), for 6 months ...
Cached Medicine Technology:Opexa Advances Monocyte Derived Islet Technology to Proof of,Principle in stz-induced NOD/SCID Mice 2Opexa Advances Monocyte Derived Islet Technology to Proof of,Principle in stz-induced NOD/SCID Mice 3A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 2A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 3A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 4A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 5
(Date:12/22/2014)... December 22, 2014 Physicians in China ... for the treatment of non-Hodgkin’s lymphoma (NHL), according to ... leading global healthcare consulting firm. MabThera is the only ... the most common form of NHL. , According to ... Barriers,” the incidence of NHL in China has been ...
(Date:12/22/2014)... 22, 2014 Explorys, the leader in ... its leadership team: Greg Yarrington as Vice President of ... Patrick Wells as Vice President of Solutions. These new ... new jobs in 2015 to support client demand for ... platform-as-a-service offerings, and growth of its partner network. ...
(Date:12/22/2014)... 2014 In recognition of Veteran’s Day, ... Hero Reward, a local organization that provides services to ... , Located on a couple hundred acres in the ... lodging, world class fishing, hunting, hiking, horseback riding, 4-wheeling, ... several years ago to support U.S. Service men and ...
(Date:12/22/2014)... New York NY (PRWEB) December 22, 2014 ... reports that a federal panel of judges has granted ... lawsuits in the U.S. District Court, Eastern District ... (JPML) issued an order on December 12 to transfer ... actions–pending in 22 districts to the Louisiana court for ...
(Date:12/22/2014)... 2014 Luxury Linen purveyor Peacock Alley ... Dallas to provide logistics and support for one of ... has a long history of giving back to the community ... this year's Toy Drive were Whataburger® and 99.5 The Wolf. ... the holidays. Providing gifts to children who would otherwise not ...
Breaking Medicine News(10 mins):Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2
... to treat bipolar disorder are more likely to get ... the //Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). ... National Institutes of Health’s (NIH) National Institute of Mental ... 2007 issue of the Archives of General Psychiatry. ...
... it off as just a part of growing older and ... ,“I was increasingly having painful menstrual periods, cramping, ... ,After running some tests, her doctor discovered that Ruma ... women, usually of childbearing age. In addition to painful menstrual ...
... Hindus and Sikhs to be allowed to hold open-air funerals, ... a charity //fighting for the cause being allowed to present ... the Anglo Asian Friendship Society, has been given permission to ... Justice Andrew Collins. ,The development follows a legal ...
... sun appears to impact more on the skin of males than ... exposed a breed of hairless mice to ultraviolet rays from a ... WebMD, The mice underwent eight- to 10-minute tanning sessions three times ... male and female mice skin cancer. ,"We found males ...
... This is one line of thought bra-burning women libbers ... book - Dressed To Kill (Avery Press, revised edition 2001) by ... had come out with claims that wearing a bra throughout ... , The authors claim to have discovered a possible trigger ...
... the chaos created by striking nurses, dentists have thrown in their ... medical card holders stand to lose access to free oral healthcare, ... voting for a withdrawal of support for the Dental Treatment Services ... scheme set up in 1994 to provide free oral ...
Cached Medicine News:Health News:Intensive Psychotherapy Effective in Treating Bipolar Disorder 2Health News:Intensive Psychotherapy Effective in Treating Bipolar Disorder 3Health News:Hope for Ending the Pain, Infertility of Endometriosis? 2Health News:Hope for Ending the Pain, Infertility of Endometriosis? 3Health News:Breast Cancer and Bra Wearing: Possibly Linked 2
... VenaCure Laser Vein Treatment. It is estimated ... worldwide have varicose veins. In the United States, ... of 60 suffer from painful and unsightly venous ... the capabilities of vascular therapy for the treatment ...
ELVeS is a new minimally-invasive laser treatment for patients with superficial vein reflux of the greater saphenous vein. The ELVeS laser treatment offers your patients an effective out-patient alt...
... technology provides practitioners with the ability to treat ... permanent hair reduction on all skin types and ... the practitioner to instantly switch to a 3, ... a simple twist of the handpiece dial while ...
... people are diagnosed with varicose veins every ... never seek treament and are apprehensive of ... them an effective alternative to conventional therapies., ... hook phlebectomy), is considered a laborious procedure ...
Medicine Products: